Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a leader in automated cell processing, announced that its CEO, Chris Xu, Ph.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Sept. 7, 2021. The conference targets institutional investors interested in the company's advancements in cell and gene therapy technologies, particularly their CAR-TXpress™ platform, enhancing CAR-T immunotherapy manufacturing. Interested investors can register for on-demand presentations and one-on-one meetings via the conference website.

News Market Reaction – THMO

-1.23%

-1.23% Session move

In the trading session that priced this news, THMO declined 1.23%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RANCHO CORDOVA, Calif., Sept. 7, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference.

If you are an institutional investor and would like to listen to the company's on-demand presentation, please click on the following link to register for the conference: www.hcwevents.com. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the company.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact: 
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact: 
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 

View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-participate-in-the-hc-wainwright-23rd-annual-global-investment-conference-301369008.html

SOURCE ThermoGenesis Holdings, Inc.

FAQ

What date is the H.C. Wainwright 23rd Annual Global Investment Conference for ThermoGenesis Holdings?

The conference will take place on September 7, 2021.

Who will present at the H.C. Wainwright conference for ThermoGenesis Holdings?

CEO Chris Xu, Ph.D. will present at the conference.

What technologies does ThermoGenesis Holdings focus on?

ThermoGenesis focuses on automated technologies for CAR-T and other cell-based therapies.

How can investors register for the ThermoGenesis Holdings conference presentation?

Investors can register through the conference website at www.hcwevents.com.

What is the CAR-TXpress™ platform offered by ThermoGenesis Holdings?

The CAR-TXpress™ platform is a semi-automated, functionally-closed system that streamlines manufacturing for CAR-T immunotherapy.